Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial

Yeul Hong Kim; Kensei Yamaguchi; Yung Jue Bang; Hiroya Takiuchi; Won Ki Kang; Atsushi Sato; Yoon Koo Kang; Junichi Sakamoto; Chigusa Abe; Yuh Sakata

doi:10.1093/jjco/hym054

Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial

Yeul Hong Kim, Kensei Yamaguchi, Yung Jue Bang, Hiroya Takiuchi, Won Ki Kang, Atsushi Sato, Yoon Koo Kang, Junichi Sakamoto, Chigusa Abe, Yuh Sakata

Department of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m² every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. Methods: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m² was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m² was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. Results: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18% (95% CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38%), anorexia in four (8%), infection in three (6%), anemia in three (6%), and abdominal pain in three (6%). Conclusions: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.

Original language	English
Pages (from-to)	501-508
Number of pages	8
Journal	Japanese Journal of Clinical Oncology
Volume	37
Issue number	7
DOIs	https://doi.org/10.1093/jjco/hym054
Publication status	Published - 2007 Jul

Bibliographical note

Funding Information:
Investigators who participated in this study were Masahiro Gotoh, Osaka Medical College Hospital, Osaka, Japan; Hoon-Kyo Kim, St Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea; Si-Young Kim, Kyung Hee University, Medical College, Seoul, Korea; Yoshito Komatsu, Hokkaido University Hospital, Hokkaido, Japan; Won Sup Lee, Gyeong-Sang National University Hospital, Jinju, Korea; Masaki Munakata, Misawa City Hospital, Aomori, Japan; Sook Ryeon Park, Research Institute and Hospital, National Cancer Center, Gyeonggi-do, Korea; Hiroshi Saito, Yamagata Prefectural Central Hospital, Yamagata, Japan; Soh Saitoh, Aomori Center Hospital, Aomori, Japan; Akinori Takagane, Iwate Medical College Hospital, Morioka, Japan; Takashi Yoshioka, Tohoku University Hospital, Sendai, Japan. This study was supported in part by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A040151), and by the non-profit organization Epidemiological & Clinical Research Network (ECRIN), Japan.

Keywords

Cisplatin
Combination chemotherapy
Gastric cancer
Paclitaxel

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jjco/hym054

Cite this

Kim, Y. H., Yamaguchi, K., Bang, Y. J., Takiuchi, H., Kang, W. K., Sato, A., Kang, Y. K., Sakamoto, J., Abe, C., & Sakata, Y. (2007). Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial. Japanese Journal of Clinical Oncology, 37(7), 501-508. https://doi.org/10.1093/jjco/hym054

@article{7f6471abc3cd41558d74f6918cedf157,

title = "Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial",

abstract = "Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m2 every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. Methods: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m2 was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m2 was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. Results: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18% (95% CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38%), anorexia in four (8%), infection in three (6%), anemia in three (6%), and abdominal pain in three (6%). Conclusions: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.",

keywords = "Cisplatin, Combination chemotherapy, Gastric cancer, Paclitaxel",

author = "Kim, {Yeul Hong} and Kensei Yamaguchi and Bang, {Yung Jue} and Hiroya Takiuchi and Kang, {Won Ki} and Atsushi Sato and Kang, {Yoon Koo} and Junichi Sakamoto and Chigusa Abe and Yuh Sakata",

note = "Funding Information: Investigators who participated in this study were Masahiro Gotoh, Osaka Medical College Hospital, Osaka, Japan; Hoon-Kyo Kim, St Vincent{\textquoteright}s Hospital, The Catholic University of Korea, Suwon, Korea; Si-Young Kim, Kyung Hee University, Medical College, Seoul, Korea; Yoshito Komatsu, Hokkaido University Hospital, Hokkaido, Japan; Won Sup Lee, Gyeong-Sang National University Hospital, Jinju, Korea; Masaki Munakata, Misawa City Hospital, Aomori, Japan; Sook Ryeon Park, Research Institute and Hospital, National Cancer Center, Gyeonggi-do, Korea; Hiroshi Saito, Yamagata Prefectural Central Hospital, Yamagata, Japan; Soh Saitoh, Aomori Center Hospital, Aomori, Japan; Akinori Takagane, Iwate Medical College Hospital, Morioka, Japan; Takashi Yoshioka, Tohoku University Hospital, Sendai, Japan. This study was supported in part by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A040151), and by the non-profit organization Epidemiological & Clinical Research Network (ECRIN), Japan.",

year = "2007",

month = jul,

doi = "10.1093/jjco/hym054",

language = "English",

volume = "37",

pages = "501--508",

journal = "Japanese Journal of Clinical Oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer

T2 - Korea-Japan collaborative study group trial

AU - Kim, Yeul Hong

AU - Yamaguchi, Kensei

AU - Bang, Yung Jue

AU - Takiuchi, Hiroya

AU - Kang, Won Ki

AU - Sato, Atsushi

AU - Kang, Yoon Koo

AU - Sakamoto, Junichi

AU - Abe, Chigusa

AU - Sakata, Yuh

N1 - Funding Information: Investigators who participated in this study were Masahiro Gotoh, Osaka Medical College Hospital, Osaka, Japan; Hoon-Kyo Kim, St Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea; Si-Young Kim, Kyung Hee University, Medical College, Seoul, Korea; Yoshito Komatsu, Hokkaido University Hospital, Hokkaido, Japan; Won Sup Lee, Gyeong-Sang National University Hospital, Jinju, Korea; Masaki Munakata, Misawa City Hospital, Aomori, Japan; Sook Ryeon Park, Research Institute and Hospital, National Cancer Center, Gyeonggi-do, Korea; Hiroshi Saito, Yamagata Prefectural Central Hospital, Yamagata, Japan; Soh Saitoh, Aomori Center Hospital, Aomori, Japan; Akinori Takagane, Iwate Medical College Hospital, Morioka, Japan; Takashi Yoshioka, Tohoku University Hospital, Sendai, Japan. This study was supported in part by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A040151), and by the non-profit organization Epidemiological & Clinical Research Network (ECRIN), Japan.

PY - 2007/7

Y1 - 2007/7

N2 - Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m2 every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. Methods: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m2 was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m2 was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. Results: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18% (95% CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38%), anorexia in four (8%), infection in three (6%), anemia in three (6%), and abdominal pain in three (6%). Conclusions: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.

AB - Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m2 every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. Methods: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m2 was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m2 was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. Results: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18% (95% CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38%), anorexia in four (8%), infection in three (6%), anemia in three (6%), and abdominal pain in three (6%). Conclusions: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.

KW - Cisplatin

KW - Combination chemotherapy

KW - Gastric cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=34548351282&partnerID=8YFLogxK

U2 - 10.1093/jjco/hym054

DO - 10.1093/jjco/hym054

M3 - Article

C2 - 17673470

AN - SCOPUS:34548351282

SN - 0368-2811

VL - 37

SP - 501

EP - 508

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

IS - 7

ER -

Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this